References
- Michielin O, van Akkooi ACJ, Ascierto PA, et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(12):1884–1901.
- Arnold M, Holterhues C, Hollestein LM, et al. Trends in incidence and predictions of cutaneous melanoma across Europe up to 2015. J Eur Acad Dermatol Venereol. 2014;28(9):1170–1178.
- Galceran J, Uhry Z, Marcos-Gragera R, et al. Trends in net survival from skin malignant melanoma in six European Latin countries: results from the SUDCAN population-based study. Eur J Cancer Prev. 2017;26:S77–S84.
- Spanish Society of Medical Oncology. (SEOM). [Cancer statistics in Spain 2020]. SEOM, 2020 ; [cited 2020 Mar 13]. https://seom.org/dmcancer/cifras-del-cancer/. Accessed 13 Mar 2020.
- Marcos-Gragera R, Vilar-Coromina N, Galceran J, et al. Rising trends in incidence of cutaneous malignant melanoma and their future projections in Catalonia, Spain: increasing impact or future epidemic? J Eur Acad Dermatol Venereol. 2010;24(9):1083–1088.
- National Collaborating Centre for Cancer (NICE). Melanoma: assessment and management. NICE guideline NG14. July 2015.
- Berrocal A, Cabañas L, Espinosa E, et al. Melanoma: diagnosis, staging, and treatment. Consensus group recommendations. Adv Ther. 2014;31(9):945–960.
- Garrison LP, Jr, Neumann PJ, Erickson P, et al. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health. 2007;10(5):326–335.
- Santaballa A, Pinto Á, Balanyà RP, et al. SEOM clinical guideline for secondary prevention (2019). Clin Transl Oncol. 2020;22(2):187–192.
- Krensel M, Schäfer I, Augustin M. Cost-of-illness of melanoma in Europe - a systematic review of the published literature. J Eur Acad Dermatol Venereol. 2019;33(3):504–510.
- Ministry of Health, Social Services and Equality. [Hospitalization report – CMBD – Discharge register: Report summary 2013]. Madrid, 2015. Spanish.
- Ministry of Health, Consumer Affairs and Social Welfare. Health Care Information and Statistics. Ministry of Health, Consumer Affairs and Social Welfare; 2019; [cited 2020 Feb 20]. Available from: https://www.mscbs.gob.es/estadEstudios/sanidadDatos/home.htm.
- Sáenz S, Conejo-Mir J, Cayuela A. [Melanoma epidemiology in Spain]. Actas Dermosifiliogr. 2005;96(7):411–418. Spanish.
- Spanish Ministry of Health. Health data, Primary care database (BDCAP). Spanish Ministry of Health; 2019; [cited 2020 Jun 8]. Available from: https://www.mscbs.gob.es/estadEstudios/sanidadDatos/home.htm.
- Cayuela A, Cayuela L, Rodríguez-Domínguez S, et al. Is melanoma mortality declining in Spain? Analysis of trends from 1975 to 2016. Br J Dermatol. 2018;179(4):991–992.
- Gutiérrez-González E, López-Abente G, Aragonés N, et al. Trends in mortality from cutaneous malignant melanoma in Spain (1982-2016): sex-specific age-cohort-period effects. J Eur Acad Dermatol Venereol. 2019;33(8):1522–1528.
- Chirlaque MD, Salmerón D, Ardanaz E, et al. Cancer survival in Spain: estimate for nine major cancers. Ann Oncol. 2010;21(Suppl 3):iii21–29.
- Berrocal A, Arance A, Castellon VE, et al. SEOM clinical guideline for the management of malignant melanoma (2017). Clin Transl Oncol. 2018;20(1):69–74.
- Guevara M, Rodríguez-Barranco M, Puigdemont M, et al. Disparities in the management of cutaneous malignant melanoma. A population-based high-resolution study. Eur J Cancer Care. 2019;28(4):e13043.
- Buja A, Rivera M, De PA, et al. Differences in direct costs of patients with stage I cutaneous melanoma: a real-world data analysis. Eur J Surg Oncol. 2020;46(6):976–981.
- Serra-Arbeloa P, Rabines-Juárez ÁO, Álvarez-Ruiz MS, et al. Cost of cutaneous melanoma by tumor stage: a descriptive analysis. Actas Dermosifiliogr. 2017;108(3):229–236.
- Grange F, Mohr P, Harries M, et al. Economic burden of advanced melanoma in France, Germany and the UK: a retrospective observational study (Melanoma Burden-of-Illness Study). Melanoma Res. 2017;27(6):607–618.